ArticleThe Lancet. Global health2018
Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.
Article in The Lancet. Global health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Protection from killed whole-cell cholera vaccines: a systematic review and meta-analysis.The Lancet. Global health · 2025Pooled it
- Estimating the proportion of clinically suspected cholera cases that are true Vibrio cholerae infections: A systematic review and meta-analysis.PLoS medicine · 2023Pooled it
- Community-level interventions for mitigating the risk of waterborne diarrheal diseases: a systematic review.Systematic reviews · 2022Pooled it
- Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.The Lancet. Infectious diseases · 2021Trial
- 5-Year effectiveness of an oral cholera vaccine in a cholera outbreak in rural Haiti: a case-control study.Lancet regional health. Americas · 2026Article
- Strategies for achieving a healthy oral cholera vaccine market: Model-enabled scenario exploration of supply and demand dynamics.PLoS neglected tropical diseases · 2026Article
- Uganda's cholera elimination journey in a cholera endemic region of Africa.PLOS global public health · 2026Article
- Impact of a multi-pronged cholera intervention in an endemic setting.PLoS neglected tropical diseases · 2025Article
- Impact of a multi-pronged cholera intervention in an endemic setting.medRxiv : the preprint server for health sciences · 2024Article
- Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study.The Lancet. Infectious diseases · 2024Article
- Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Article
- Genomic epidemiology of Vibrio cholerae during a mass vaccination campaign of displaced communities in Bangladesh.Nature communications · 2023Article
- A polyvalent multiepitope protein cross-protects againstProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Optimizing one-dose and two-dose cholera vaccine allocation in outbreak settings: A modeling study.PLoS neglected tropical diseases · 2022Article
- Oral Cholera Vaccine Efficacy and Effectiveness.Vaccines · 2021Review
- Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India.Epidemiology and infection · 2021Article
- Factors associated with diarrheal disease among children aged 1-5 years in a cholera epidemic in rural Haiti.PLoS neglected tropical diseases · 2021Article
- Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundNo study of long-term protection following killed oral cholera vaccination has been done outside of the historically cholera-endemic areas of south Asia, or has examined protection after a single-dose vaccination regimen. To address this, we examined the duration of protection of the standard two-dose regimen and an incomplete regimen of one dose up to 4 years after vaccination in Haiti.
methodsIn the setting of two-dose vaccination campaigns with a killed, bivalent, whole-cell oral cholera vaccination, we did a case-control study from October, 2012 through November, 2016. Eligible participants were required to be resident in the vaccine catchment area (Artibonite Department or Central Department) where they were recruited at the start of the study; and be eligible for the vaccination campaign (ie, aged ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign). Patients with cholera had a positive stool culture and were recruited from cholera treatment centres. Community controls were matched to people with cholera by age group, time, and neighbourhood. We did adjusted matched regression analyses to calculate vaccine effectiveness and examine heterogeneity in effectiveness over time. The primary outcome was the effectiveness of one and two oral cholera doses as compared with zero doses from 2 months to 48 months after vaccination, measured by self reporting.
findingsAmong 178 people assigned to the case group and 706 people assigned to the control group, we found no evidence that two-dose effectiveness decreased during follow-up. In adjusted analyses, the average cumulative 4 year effectiveness for two doses was 76% (95% CI 59-86). In contrast, single-dose effectiveness decreased over time in a log-linear fashion, with a predicted vaccine effectiveness of 79% at the end of 12 months (95% CI 43-93), which declined to zero before the end of the second year.
interpretationIn a setting of epidemic and newly endemic cholera in Haiti, single-dose vaccination with killed, bivalent, whole-cell oral cholera vaccination provided short-term protection; however, vaccination with two doses was required for long-term protection, which lasted up to 4 years after vaccination. These results add to the evidence in support of the use of killed, bivalent, whole-cell oral cholera vaccination as part of comprehensive cholera control plans.
fundingUS National Institute of Allergy and Infectious Diseases of the National Institutes of Health and the Bill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.